The Influence of Anatomic Deformities on the Clinical Efficacy in the Patients With Patellar Dislocation
Launched by PEKING UNIVERSITY THIRD HOSPITAL · Feb 7, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how certain physical differences in the knee can affect the success of treatment for patients who experience patellar dislocation, which is when the kneecap moves out of its normal position. Researchers will gather information from patients, including imaging tests like X-rays and MRIs, as well as their medical histories and physical exams. This will help identify any anatomical issues that might make it more likely for someone to experience a dislocated kneecap and see how these issues impact the effectiveness of treatments.
To be eligible for the trial, participants must have had a patellar dislocation but cannot have significant knee ligament injuries or prior fractures or surgeries in their lower limbs. Additionally, those whose dislocations were caused by serious accidents won't be included. The trial is currently recruiting participants of all genders, aged between 5 and 14 years. People who join can expect to undergo various tests to help researchers learn more about the connections between knee structure and treatment outcomes, ultimately aiming to improve care for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • -Patients with patellar dislocation.
- Exclusion Criteria:
- • Patients with significant ligamentous knee injury.
- • Previous fracture or surgery of the lower limb.
- • Patellar dislocation caused by car accidents or other high-energy force directly on the patella.
About Peking University Third Hospital
Peking University Third Hospital is a leading medical institution in China, renowned for its commitment to advanced healthcare, innovative research, and comprehensive clinical services. As a prominent sponsor of clinical trials, the hospital emphasizes the integration of cutting-edge scientific research with patient-centered care to enhance therapeutic outcomes. With a multidisciplinary approach, the institution fosters collaboration among top-tier medical professionals and researchers, striving to contribute to the global medical community through rigorous clinical studies that address pressing health challenges. Its dedication to ethical standards and regulatory compliance ensures the safety and efficacy of new treatments, ultimately aiming to improve patient care and outcomes on both a national and international scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Lin Lin
Study Director
Peking University Third Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials